Company Overview of AC Immune SA
AC Immune SA, a biopharmaceutical company, develops vaccines, antibodies, and small molecules for conformational diseases and cancer. The company develops active and passive immunotherapies against Alzheimer's disease using its molecular technology platform. It offers ACI-24, an Alzheimer's disease vaccine, which is designed to act as an active vaccine stimulating the patient's immune system to produce beta-sheet conformation-specific antibodies that prevent plaque deposition or enhance clearance of plaques; ACI-01-Ab7, a monoclonal antibody and passive immunotherapy; and Morphomers and ACI-91, the small molecules products. AC Immune SA was founded in 2003 and is based in Lausanne, Switzerla...
PSE Building B - EPFL
Founded in 2003
Key Executives for AC Immune SA
Co-Founder and Member of the Scientific Advisory Board
Compensation as of Fiscal Year 2015.
AC Immune SA Key Developments
Nestle Institute of Health Sciences Partners with AC Immune to Develop Alzheimer's Test
Sep 23 15
Nestle Institute of Health Sciences (NIHS) and AC Immune announced new partnership to develop an early Alzheimer's diagnostic test. NIHS will for its part provide a technology platform to the research program to help identify Tau in blood plasma and cerebrospinal fluid (CSF).
AC Immune Seeks IPO
Jun 9 15
AC Immune SA is seeking an IPO. AC Immune will consider an initial public offering or a sale once its experimental Alzheimer’s treatment enters late-stage trials.
AC Immune (Switzerland) Enter into an Exclusive Global License and Research Agreement with Janssen Pharmaceuticals
Jan 13 15
AC Immune (Switzerland) has entered into an exclusive global license and research agreement with Janssen Pharmaceuticals, which is focused on the development and commercialization of anti-Tau therapeutic vaccines for the treatment of Alzheimer's disease and other tauopathies, such as frontotemporal dementia, progressive supranuclear palsy, and amyotrophic lateral sclerosis. Based on the terms of the transaction, AC Immune will receive an upfront payment, as well as potential research, development, and commercialization milestone payments worth up to CHF 500 million (USD 509 million). Janssen will be responsible for the development of AC Immune's lead therapeutic vaccine, ACI-35, following the Phase Ib completion for Alzheimer's disease, as well as a potential second indication outside of the disease. Janssen will also be responsible for manufacturing and commercialization of ACI-35. The agreement also involved a three-year co-research collaboration for the potential characterization and development of novel vaccines for tauopathies. AC Immune will be eligible for tiered royalties on net sales from products resulting from the collaboration.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries